文献速递造血干细胞移植与细胞治疗

贝鲁木舒地尔与最佳可用疗法治疗美国慢性移植物抗宿主病的疗效与安全性比较

Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States.
PubMed 文献 · Blood Adv · 2026-01-01

本研究基于美国8个中心2015年3月至2024年的回顾性数据,纳入196例患者的113个贝鲁木舒地尔治疗线和245个最佳可用疗法(BAT)治疗线,比较两者在既往接受2至5线治疗失败的cGVHD患者中的疗效与安全性。贝鲁木舒地尔组6个月总缓解率为38.7%,BAT组为26.8%,贝鲁木舒地尔改善44.2%(单侧95%CI 4.4至无穷;P=0.031);1年无失败生存率分别为61.2%和47.8%,差异13.5%(95%CI 1.5-100;P=0.032)。安全性方面,贝鲁木舒地尔组27%的治疗线报告不良事件,BAT组为36%。

要点

  • 贝鲁木舒地尔组6个月ORR为38.7%,BAT组为26.8%(P=0.031)。
  • 贝鲁木舒地尔组1年无失败生存率为61.2%,BAT组为47.8%(P=0.032)。
  • 不良事件发生率贝鲁木舒地尔组27%,BAT组36%。

核心结论

  • 在既往接受2至5线治疗失败的cGVHD患者中,贝鲁木舒地尔较BAT改善了临床结局,安全性与其已知特征一致。

研究设计与样本

  • 回顾性研究,收集2015年3月至2024年美国8个中心196例患者的数据,贡献113个贝鲁木舒地尔治疗线和245个BAT治疗线。
  • 主要终点为6个月总缓解率(ORR),定义为基于2014年美国国立卫生研究院共识标准、医生评估或泼尼松剂量减少≥50%且无cGVHD进展的完全或部分缓解比例;死亡、复发和开始新治疗线视为无缓解。
  • 采用靶向最大似然估计(TMLE)比较贝鲁木舒地尔与BAT的6个月ORR和1年无失败生存率。

主要发现

  • 贝鲁木舒地尔组6个月ORR为38.7%,BAT组为26.8%,贝鲁木舒地尔改善44.2%(单侧95%CI 4.4至无穷;P=0.031)。
  • 贝鲁木舒地尔组1年无失败生存率为61.2%,BAT组为47.8%,差异13.5%(95%CI 1.5-100;P=0.032)。
  • 贝鲁木舒地尔组27%的治疗线报告不良事件,BAT组为36%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Belumosudil was approved by the Food and Drug Administration in the United States for the treatment of relapsed/refractory chronic graft-versus-host disease (cGVHD) based on a randomized phase 2 trial comparing 2 belumosudil doses. The efficacy and safety of belumosudil vs the best available therapy (BAT) has not been studied. Applying rigorous statistical methodology to real-world data, this study estimated the efficacy of belumosudil vs BAT in cGVHD patients whose disease failed to respond to 2 to 5 prior lines of therapy (LOTs). Retrospective data between March 2015 and 2024 were collected across 8 US sites for 196 patients, contributing 113 belumosudil and 245 BAT LOTs. The primary outcome was 6-month overall response rate (ORR), defined as the proportion of complete or partial responses based on 2014 National Institutes of Health consensus criteria, physician assessment, or corticosteroid dose taper of ≥50% without cGVHD progression. Death, relapse, and beginning a new LOT were considered a lack of response. Targeted maximum likelihood estimation (TMLE) was used to estimate the 6-month ORR following belumosudil vs BAT (38.7% vs 26.8%, respectively) or 44.2% improvement with belumosudil (1-sided 95% confidence interval [CI], [4.4 to ∞]; P = .031). TMLE was also used to estimate 1-year failure-free survival when treated with belumosudil (61.2%) or BAT (47.8%), a 13.5% difference (95% CI, 1.5-100; P = .032). Descriptive assessment of safety showed adverse events recorded in 27% of belumosudil and 36% of BAT LOTs. Findings demonstrated that belumosudil improved clinical outcomes compared to BAT in cGVHD patients with 2 to 5 prior LOTs, and safety was consistent with belumosudil's established profile.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hall K, Lazaryan A, van der Laan M, et al. Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States. Blood Adv. 2026. PMID: 40875591. doi:10.1182/bloodadvances.2025015832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。